Results 221 to 230 of about 187,335 (337)

Assessing gout risk associated with GLP‐1 therapy in obese patients with type 2 diabetes: A retrospective cohort study

Rheumatology &Autoimmunity, EarlyView.
Justin Riley Lam, Emmanuel Otabor, Laith Alomari, Maxim Barnett, Bal Subedi, Het Hirpara, Freya Thummar   +6 more
wiley   +1 more source

Polypharmacy in mice disrupts left ventricular function and structure and promotes proteome reorganisation in an age‐ and sex‐specific fashion

British Journal of Pharmacology, EarlyView.
Background and Purpose Most older people use polypharmacy (≥5 medications), particularly those with cardiovascular disease. The effects of polypharmacy on the cardiovascular system are not well described. We examined the effect of a chronic polypharmacy regimen on left ventricular (LV) function, structure and proteome in young and old mice of both ...
Trang Tran, Kevin Winardi, Scott P. Levick, Alexander Widiapradja, Gizem Gemikonakli, Susan E. Howlett, Matthew J. McKay, Mark P. Molloy, John Mach, Sarah N. Hilmer   +9 more
wiley   +1 more source

Purine Chemistry in the Early RNA World at the Origins of Life: From RNA and Nucleobases Lesions to Current Key Metabolic Routes. [PDF]

Chembiochem
Décout JL, Maurel MC.
europepmc   +1 more source

Klebsiella pneumoniae contributes to altered cytotoxicity of thiopurines in vitro: Possible implications of biotransformation and bacterial metabolism

British Journal of Pharmacology, EarlyView.
Abstract Background and purpose Thiopurines are used in paediatric inflammatory bowel disease (IBD), but some patients do not respond. Because the gut microbiota influences drug efficacy and IBD‐patient microbiota presents increased bacterial abundance, we investigated the impact of candidate Enterobacteriaceae on drug cytotoxicity, metabolism and ...
Martina Franzin, Cristina Lagatolla, Sofia Sindici Forgiarini, Mathias Haag, Sylvia Karin Neef, Manola Comar, Elke Schaeffeler, Barbara Bellich, Matteo Bramuzzo, Giuliana Decorti, Marianna Lucafò, Ute Hofmann, Matthias Schwab, Gabriele Stocco   +13 more
wiley   +1 more source

P058: Design of the prospective study of the clinical, laboratory, and dietary determinates of outcomes in purine and pyrimidine metabolism disorders

Genetics in Medicine Open
Shannon Haines, Katharine Chaillet, Oleg Shchelochkov   +2 more
doaj  

Phosphoribosylformylglycinamidine Synthase (PFAS) Deficiency: Clinical, Genetic and Metabolic Characterisation of a Novel Defect in Purine de Novo Synthesis. [PDF]

J Inherit Metab Dis
Zikanova M, Skopova V, Stuurman KE, Baresova V, Souckova O, Hnizda A, Krijt M, Bleyer AJ, Zeman J, Kmoch S.   +9 more
europepmc   +1 more source

Pharmacological evaluation of non‐nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation in traumatic brain injury

British Journal of Pharmacology, EarlyView.
Background and purpose Traumatic brain injury (TBI) is considered to be a leading cause of mortality and disability worldwide. After TBI, innate immunity is rapidly activated in response to damage‐associated molecular patterns, such as ATP release, recognised by P2X7 receptors.
Inés Valencia, Andrea Pastor‐Martínez, Céline Decouty‐Pérez, Ana Belen Lopez‐Rodriguez, María Álvarez‐Rubal, Eva Ramos, Francesco Calzaferri, Jorge Zamorano‐Fernández, Javier Giner‐García, Alexis J. Palpán‐Flores, Víctor Rodríguez‐Domínguez, Javier Rodríguez de Cía, Borja J. Hernández‐García, Alejandro Romero, Cristóbal de los Ríos, Javier Egea   +15 more
wiley   +1 more source

Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis. [PDF]

J Biol Chem
Qi Z, Luo J, Liu W, Xu Y, Ma Y, Hu S, Shen X, Du X, Xiang W.   +8 more
europepmc   +1 more source

RÔLE OF 4-AMINOIMIDAZOLE-5-CARBOXAMIDE IN PURINE SYNTHESIS BY ESCHERICHIA COLI

, 1952
Ernst Bergmann, R. Ben‐Ishai, Benjamin E. Volcani   +2 more
openalex   +1 more source

Cannabinoid CB2 receptor‐mediated analgesia: mechanism‐based insights and therapeutic potential

British Journal of Pharmacology, EarlyView.
Agonists of the cannabinoid 2 (CB2) receptor have shown promise for the treatment of pain in a variety of animal models. However, despite current preclinical evidence supporting the use of CB2 agonists for pain, successful translation of findings from preclinical models to human patients is lacking.
Kelsey G. Guenther, Andrea G. Hohmann
wiley   +1 more source